Supernus Pharmaceuticals Inc (SUPN)
Debt-to-equity ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | 379,252 | 361,751 |
| Total stockholders’ equity | US$ in thousands | 1,035,730 | 921,516 | 886,204 | 815,851 | 744,858 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.46 | 0.49 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $1,035,730K
= 0.00
The debt-to-equity ratio of Supernus Pharmaceuticals Inc has shown a decreasing trend over the years, declining from 0.49 in December 31, 2020, to 0.46 in December 31, 2021, and reaching 0.00 in December 31, 2022, 2023, and 2024. This trend suggests that the company has been reducing its reliance on debt financing and moving towards a more conservative capital structure with lower levels of debt relative to equity. A debt-to-equity ratio of 0.00 indicates that the company has no debt on its balance sheet, which can be seen as a positive sign of financial strength and stability.
Peer comparison
Dec 31, 2024